Evaluation of Imatinib (GLIVEC) After Induction Therapy in Patients Aged More Than 55 Years With Philadelphia Positive Acute Lymphoblastic Leukaemia (Ph+ ALL) : a Non Randomised, Controlled, Open, Multicentric, International Phase II Clinical Study (CSTI 571 AFR09 Trial)
Phase 2
55 Years
90 Years
55 Years
90 Years
Open (Enrolling)
Both
Acute Lymphocytic Leukemia
Both
Acute Lymphocytic Leukemia
Trial Information
Evaluation of Imatinib (GLIVEC) After Induction Therapy in Patients Aged More Than 55 Years With Philadelphia Positive Acute Lymphoblastic Leukaemia (Ph+ ALL) : a Non Randomised, Controlled, Open, Multicentric, International Phase II Clinical Study (CSTI 571 AFR09 Trial)
Inclusion Criteria:
- Ph+ ALL patients
- 55 years or older
- Signed written informed consent
Exclusion Criteria:
- CML in transformation
- Concomitant malignancy
- Previous treatment by Imatinib
- Severe organ condition
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label
Outcome Measure:
Impact of Imatinib on survival in elderly patients with Ph+ALL
Principal Investigator
Xavier THOMAS, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Hospices Civils de Lyon
Authority:
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study ID:
2002.280
NCT ID:
NCT00149136
Start Date:
August 2002
Completion Date:
Related Keywords:
- Acute Lymphocytic Leukemia
- Acute Lymphocytic Leukemia,
- Ph+,
- elderly patients,
- Imatinib
- Leukemia
- Leukemia, Lymphoid
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
Name | Location |
|---|
